Year-end Report 2018
Summary of Q4 Financial overview October 1 – December 31, 2018 · Net sales amounted to SEK 0.0 M (0.0) · Loss for the period was SEK 111.4 M (loss: 66.2) · Loss per share, before and after dilution, was 2.53 (loss: 1.68) SEK · On December 31 cash and cash equivalents amounted to SEK 375.6 M (404.1) Significant events during the period October 1 to December 31, 2018 · At the company's Capital Markets Day in December, an updated strategy for Oncopeptides' business was presented · At the company's extraordinary general meeting in December, Dr Jennifer Jackson was
